Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults

Next Previous
Trial Profile

A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCEL
  • Sponsors Ardelyx

Most Recent Events

  • 20 Feb 2026 According to an Ardelyx media release, pending the outcome of the Phase 3 trial, the company intends to submit a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for the CIC indication.
  • 06 Feb 2026 New trial record
  • 28 Jan 2026 According to Ardelyx media release, the enrollment in ACCEL is expected throughout 2026, with topline data read out in the second half of 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top